Replimune Group Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced the appointment of Dieter Weinand as Chairman of the Board of Directors and the new appointment of Paolo Pucci to the Board of Directors, effective immediately.
April 2, 2020
· 5 min read